Junya Yamaguchi

ORCID: 0000-0002-4344-5750
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Glioma Diagnosis and Treatment
  • Meningioma and schwannoma management
  • Brain Metastases and Treatment
  • CNS Lymphoma Diagnosis and Treatment
  • Radiomics and Machine Learning in Medical Imaging
  • Lymphoma Diagnosis and Treatment
  • Mathematical Biology Tumor Growth
  • Neurofibromatosis and Schwannoma Cases
  • Cancer Genomics and Diagnostics
  • MicroRNA in disease regulation
  • Neuroblastoma Research and Treatments
  • Virus-based gene therapy research
  • Chronic Lymphocytic Leukemia Research
  • Pituitary Gland Disorders and Treatments
  • Pancreatic and Hepatic Oncology Research
  • Organ Transplantation Techniques and Outcomes
  • Epigenetics and DNA Methylation
  • Epilepsy research and treatment
  • Extracellular vesicles in disease
  • Cancer-related Molecular Pathways
  • Immune Cell Function and Interaction
  • Genetic factors in colorectal cancer
  • Vascular Procedures and Complications
  • Vascular Malformations Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies

Nagoya University
2019-2025

Nagoya University Hospital
2018-2024

Kokura Memorial Hospital
2021

Ichinomiya Municipal City Hospital
2018

Japanese Red Cross Nagoya Daini Hospital
2016-2017

Fujitsu (Japan)
2017

Red Cross Hospital
2016

Japanese Foundation For Cancer Research
2014-2015

Fukui CardioVascular Center
2015

Tokyo University of Agriculture
2010

There are no accurate mass screening methods for early detection of central nervous system (CNS) tumors. Recently, liquid biopsy has received a lot attention less-invasive cancer screening. Unlike other cancers, CNS tumors require efforts to find biomarkers due the blood–brain barrier, which restricts molecular exchange between parenchyma and blood. Additionally, because satisfactory way collect urinary is lacking, urine-based not been fully investigated despite fact that it some advantages...

10.1021/acsami.1c01754 article EN cc-by-nc-nd ACS Applied Materials & Interfaces 2021-04-01

OBJECTIVE Lower-grade gliomas (LGGs) are often observed within eloquent regions, which indicates that tumor resection in these areas carries a potential risk for neurological disturbances, such as motor deficit, language disorder, and/or neurocognitive impairments. Some patients with frontal tumors exhibit severe impairments of function, including working memory and spatial awareness, after removal. The aim this study was to investigate functional outcomes LGGs both the dominant nondominant...

10.3171/2019.3.jns19211 article EN Journal of neurosurgery 2019-05-17

Abstract Background Recent comprehensive studies have revealed several molecular alterations that are frequently found in meningiomas. However, effective treatment reagents targeting specific not yet been identified because of the limited number representative research models Methods We performed organoid cultures using meningioma cells and tumor tissues. Using immunohistochemistry analyses consisting whole-exome sequencing, RNA-seq, DNA methylation analyses, we compared histological...

10.1093/neuonc/noab155 article EN Neuro-Oncology 2021-06-30

Glioblastoma (GB) is the most common and aggressive primary malignant brain tumor in adults. To date, no effective treatment has been reported for recurrent GB (rGB). Long noncoding RNA taurine upregulated gene 1 (TUG1), which highly expressed GB, resolves formation of R-loops, thereby maintaining growth. TUG1-targeting antisense oligonucleotide (ASO) (TUG1ASO) a nucleotide therapeutic with drug delivery system that targets TUG1, demonstrating efficacy against mouse models. This multicenter,...

10.1186/s12885-025-13623-0 article EN cc-by-nc-nd BMC Cancer 2025-02-13

Diffuse hemispheric glioma H3 G34-mutant (DHG) has been identified as a distinct pediatric-type high-grade glioma, according to the World Health Organization (WHO) classification of central nervous system tumors. Widely accepted treatment options include surgery, radiation, and conventional chemotherapy. However, efficacy surgical resection remains unclear. Although there are some reports, comprehensive understanding clinical characteristics, pathogenesis, outcomes DHG is insufficient...

10.1186/s40478-025-01945-w article EN cc-by-nc-nd Acta Neuropathologica Communications 2025-02-27

The myeloid differentiation primary response gene 88 (MYD88) L265P mutation is a disease-specific of central nervous system lymphoma (PCNSL) among the tumors. Accordingly, this considered reliable diagnostic molecular marker PCNSL. As intra-operative diagnosis PCNSL sometimes difficult to achieve using histological examinations alone, detection MYD88 could be effective for accurate Herein, we aimed develop novel rapid genotyping (GeneSoC) real-time polymerase chain reaction (PCR) based on...

10.1111/cas.15762 article EN cc-by-nc-nd Cancer Science 2023-03-01

The study of genetic alterations and molecular biology in central nervous system (CNS) tumors has improved the accuracy estimations patient prognosis tumor categorization. Therefore, updated 2021 World Health Organization (WHO) classification includes various diagnostic genes, molecules, pathways for diagnosis, as well histological findings. These findings are expected both to have applications facilitate new targeted therapies that target tumor-specific changes biology. Intramedullary...

10.14245/ns.2244168.084 article EN cc-by-nc Neurospine 2022-05-15

Extracellular vesicles (EVs) contain a subset of proteins, lipids, and nucleic acids that maintain the characteristics parent cell. Immunotherapy using EVs has become focus research due to their unique features bioinspired applications in cancer treatment. Unlike conventional immunotherapy tumor fragments, can be easily obtained from bodily fluids without invasive actions. We previously fabricated nanowire devices were specialized for EV collection, but they not suitable cell culturing. In...

10.1021/acsami.4c00283 article EN cc-by ACS Applied Materials & Interfaces 2024-05-28

Abstract Background This study aimed to investigate what treatment are selected for malignant brain tumors, particularly glioblastoma (GBM) and primary central nervous system lymphoma (PCNSL), in real-world Japan the costs involved. Methods We conducted a questionnaire survey regarding selections newly diagnosed GBM PCNSL treated between July 2021 June 2022 among 47 institutions Clinical Oncology Group-Brain Tumor Study Group. calculated total cost per month of initial therapy or PCNSL....

10.1093/jjco/hyae116 article EN cc-by-nc Japanese Journal of Clinical Oncology 2024-09-02

Abstract Diffuse midline glioma, H3 K27M-mutant is a lethal brain tumor located in the thalamus, stem, or spinal cord. K27M encoded by mutation of histone gene such as H3F3A plays pivotal role tumorigenesis this type glioma. Although several studies have revealed comprehensive genetic and epigenetic profiling, prognostic factors these tumors not been identified to date. In various cancers, oncogenic driver genes found exhibit characteristic copy number alterations termed mutant allele...

10.1186/s40478-020-0882-4 article EN cc-by Acta Neuropathologica Communications 2020-02-05

The transcriptome analysis of injured Xenopus laevis tadpole and mice suggested that Neurod4L.S., a basic-helix-loop-helix transcription factor, was the most promising factor to exert neuroregeneration after spinal cord injury (SCI) in mammals. We generated pseudotyped retroviral vector with neurotropic lymphocytic choriomeningitis virus (LCMV) envelope deliver murine Neurod4 undergoing SCI. SCI induced ependymal cells neural stem (NSCs) central canal. LCMV envelope-based pseudotypedvector...

10.1016/j.isci.2021.102074 article EN cc-by-nc-nd iScience 2021-01-20

Abstract Isocitrate dehydrogenase-mutant low-grade gliomas (IDHmut-LGG) grow slowly but frequently undergo malignant transformation, which eventually leads to premature death. Chemotherapy and radiotherapy treatments prolong survival, can also induce genetic (or epigenetic) alterations involved in transformation. Here, we developed a mathematical model of tumor progression based on serial volume data treatment history 276 IDHmut-LGGs classified by chromosome 1p/19q codeletion...

10.1158/0008-5472.can-21-0985 article EN cc-by-nc-nd Cancer Research 2021-07-31

Li-Fraumeni syndrome (LFS) is an autosomal dominant tumor predisposition caused by heterozygous germline mutations or deletions in the TP53 suppressor gene. Central nervous system tumors, such as choroid plexus medulloblastomas, and diffuse gliomas, are frequently found patients with LFS. Although molecular profiles of gliomas that develop pediatric LFS have been elucidated, those adults limited. Recently, divided into pediatric- adult-type based on their distinct profiles. In present study,...

10.1186/s40478-024-01762-7 article EN cc-by Acta Neuropathologica Communications 2024-04-11

Neurofibromatosis type 1 (NF1) is an autosomal dominant syndrome caused by germline alteration of the NF1 gene. Among various NF1-related manifestations, obstructive hydrocephalus especially in adult cases less frequently found. We report two exhibiting due to aggressive posterior fossa tumor pathological characteristics pilocytic astrocytoma as manifestations. In these cases, we performed endoscopic third ventriculostomy (ETV) and biopsy initial treatment. The diagnosis conventional...

10.7759/cureus.58697 article EN Cureus 2024-04-21

Abstract Patients with diffuse frontal gliomas often present post‐operative apathy after tumour removal. However, the association between and removal of from lobe remains unknown. This study aimed to investigate factors influencing in patients gliomas. We compared demographics clinical characteristics without a cohort 54 who underwent awake brain mapping for The frequency parameters such as left‐sided involvement, high‐grade types (WHO grades III, IV), main location anterior cingulate gyrus...

10.1111/jnp.12345 article EN Journal of Neuropsychology 2023-09-20

Abstract Background Rituximab, high‐dose methotrexate (HD‐MTX), procarbazine and vincristine (R‐MPV), has significantly prolonged the survival of patients with primary central nervous system lymphoma (PCNSL), but predictive factors for response to R‐MPV have not yet been investigated. Herein, we investigated correlation MYD88 L265P CD79B Y196 mutations, which are most frequently found molecular alterations in PCNSL, prognosis PCNSL treated R‐MPV. Methods We long‐term clinical course status...

10.1002/cam4.5512 article EN cc-by Cancer Medicine 2022-12-07

In humans, hearing is a major factor in quality of life. Mouse models are important tools for the discovery genes responsible genetic loss, often enabling analysis processes that regulate onset deafness humans. Thus far, at least 400 mutants have been discovered laboratory mouse populations and used study deafness. Here we report new spontaneous recessive Rinshoken shaker/waltzer (rsv) mutant derived from our in-house C57BL/6J stock, which exhibits circling and/or head-tossing behaviour...

10.1538/expanim.59.57 article EN EXPERIMENTAL ANIMALS 2010-01-01

OBJECTIVE The current study aimed to evaluate the treatment outcomes and toxicities of patients with intracranial germ cell tumors (GCTs). METHODS This retrospectively included 110 consecutive (70 in germinomatous group 40 nongerminomatous GCT [NGGCT] groups) receiving surgery, platinum-based chemotherapy, radiotherapy for newly diagnosed primary GCTs. In authors’ protocol, GCTs were further divided into following four groups: NGGCT groups (mature teratoma, intermediate prognosis, or poor...

10.3171/2020.6.jns20638 article EN Journal of neurosurgery 2020-10-02

Abstract Isocitrate dehydrogenase wild-type ( IDH wt) diffuse astrocytomas feature highly infiltrative patterns, such as a gliomatosis cerebri growth pattern with widespread involvement. Among these tumors, localized wt histologically are rarer than the type. The aim of this study was to assess and describe clinical, radiographic, histopathological, molecular characteristics rare type thereby provide more information on how its features affect clinical prognoses outcomes. We retrospectively...

10.1038/s41598-022-25928-2 article EN cc-by Scientific Reports 2023-01-16
Coming Soon ...